Vir Biotechnology, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Vir Biotechnology, Inc. (VIR) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$1.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-05
- Vir Biotechnology, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$1.10M.
- Vir Biotechnology, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$400.00K, a 136.36% decline year-over-year.
- Vir Biotechnology, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $0.00.
- Vir Biotechnology, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $300.00K, a 92.50% decline year-over-year.
- Vir Biotechnology, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was $1.40M, a 55.56% increase from fiscal 2023.
- Vir Biotechnology, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $900.00K.
- Vir Biotechnology, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$8.40M, a 1033.33% decline from fiscal 2021.
- Vir Biotechnology, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was $900.00K, a 800.00% increase from fiscal 2020.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.50M 10-Q · filed 2026-08-05 | -$1.50M derived: sum of 3 quarters · filed 2026-08-05 | -$1.20M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$400.00K 10-Q · filed 2026-05-07 | -$400.00K derived: sum of 2 quarters · filed 2026-08-05 | -$100.00K derived: sum of 3 quarters · filed 2026-08-05 | -$400.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-05 | $300.00K derived: sum of 2 quarters · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $1.10M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $1.10M 10-Q · filed 2025-11-05 | -$500.00K derived: sum of 4 quarters · filed 2026-02-23 | |
| 2025-06-30 | -$300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $800.00K 10-Q · filed 2025-08-06 | -$800.00K derived: sum of 3 quarters · filed 2026-02-23 | $3.20M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2025-03-31 | $1.10M 10-Q · filed 2025-05-08 | -$500.00K derived: sum of 2 quarters · filed 2026-02-23 | $3.50M derived: sum of 3 quarters · filed 2026-02-23 | $3.00M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $2.40M derived: sum of 2 quarters · filed 2026-02-23 | $1.90M derived: sum of 3 quarters · filed 2026-02-23 | $1.40M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $3.50M derived: sum of 2 quarters · filed 2024-11-04 | $3.00M 10-Q · filed 2024-11-04 | $5.10M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2024-06-30 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.00M 10-Q · filed 2024-08-01 | $1.10M derived: sum of 3 quarters · filed 2025-02-27 | $2.10M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2024-03-31 | -$500.00K 10-Q · filed 2024-05-03 | $1.60M derived: sum of 2 quarters · filed 2025-02-27 | $2.60M derived: sum of 3 quarters · filed 2025-02-27 | -$2.10M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.10M derived: sum of 2 quarters · filed 2025-02-27 | -$1.60M derived: sum of 3 quarters · filed 2025-02-27 | $900.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$3.70M derived: sum of 2 quarters · filed 2023-11-03 | -$1.20M 10-Q · filed 2023-11-03 | -$21.20M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2023-06-30 | -$4.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$2.20M 10-Q · filed 2023-08-04 | -$22.20M derived: sum of 3 quarters · filed 2024-02-26 | ||
| 2023-03-31 | $2.50M 10-Q · filed 2023-05-08 | -$17.50M derived: sum of 2 quarters · filed 2024-02-26 | |||
| 2022-12-31 | -$20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$8.40M 10-K · filed 2024-02-26 | $8.40M 10-K · filed 2023-02-28 | ||
| 2022-09-30 | $11.60M 10-Q · filed 2022-11-03 | ||||
| 2021-12-31 | $900.00K 10-K · filed 2023-02-28 | ||||
| 2020-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$300.00K derived: sum of 2 quarters · filed 2022-02-28 | -$900.00K derived: sum of 3 quarters · filed 2022-02-28 | $100.00K 10-K · filed 2022-02-28 | |
| 2020-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$800.00K derived: sum of 2 quarters · filed 2020-11-10 | $200.00K 10-Q · filed 2020-11-10 | $100.00K derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-06-30 | -$600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $400.00K 10-Q · filed 2020-08-11 | $300.00K derived: sum of 3 quarters · filed 2021-02-25 | ||
| 2020-03-31 | $1.00M 10-Q · filed 2020-05-12 | $900.00K derived: sum of 2 quarters · filed 2021-02-25 | |||
| 2019-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $100.00K 10-K · filed 2021-02-25 | |||
| 2019-09-30 | $200.00K 10-Q · filed 2019-11-19 | ||||
| 2018-12-31 | -$14.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |